Stock Track | Avadel Pharmaceuticals Soars 10.76% Pre-Market on Strong Q1 Results and Raised Guidance

Stock Track

May 07, 2025

Avadel Pharmaceuticals plc (AVDL) shares surged 10.76% in pre-market trading on Wednesday following the company's release of its first-quarter 2025 financial results and an upward revision of its full-year guidance.

The specialty pharmaceutical company reported a narrower-than-expected loss for Q1, with earnings per share (EPS) of -$0.05, beating analyst estimates. While the company still posted a net loss of $4.92 million, this represents a significant improvement compared to previous quarters. Avadel's net product revenue for the quarter reached $52.511 million, indicating strong sales performance.

Investors were particularly encouraged by Avadel's optimistic outlook for 2025. The company raised its full-year guidance, now expecting to generate between $255 million and $265 million in net product revenue. This upward revision suggests growing confidence in the company's product pipeline and market position. The combination of better-than-expected quarterly results and an improved annual forecast appears to be driving the substantial pre-market rally in Avadel's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1103586180"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103586180\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103586180?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-07 19:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103586180","market":"nz","top_or_hot":-1,"title":"Stock Track | Avadel Pharmaceuticals Soars 10.76% Pre-Market on Strong Q1 Results and Raised Guidance","media":"Stock Track","content":"<p>Avadel Pharmaceuticals plc (AVDL) shares surged 10.76% in pre-market trading on Wednesday following the company's release of its first-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The specialty pharmaceutical company reported a narrower-than-expected loss for Q1, with earnings per share (EPS) of -$0.05, beating analyst estimates. While the company still posted a net loss of $4.92 million, this represents a significant improvement compared to previous quarters. Avadel's net product revenue for the quarter reached $52.511 million, indicating strong sales performance.</p>\n\n<p>Investors were particularly encouraged by Avadel's optimistic outlook for 2025. The company raised its full-year guidance, now expecting to generate between $255 million and $265 million in net product revenue. This upward revision suggests growing confidence in the company's product pipeline and market position. The combination of better-than-expected quarterly results and an improved annual forecast appears to be driving the substantial pre-market rally in Avadel's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Avadel Pharmaceuticals Soars 10.76% Pre-Market on Strong Q1 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Avadel Pharmaceuticals Soars 10.76% Pre-Market on Strong Q1 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-07 19:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Avadel Pharmaceuticals plc (AVDL) shares surged 10.76% in pre-market trading on Wednesday following the company's release of its first-quarter 2025 financial results and an upward revision of its full-year guidance.</p>\n\n<p>The specialty pharmaceutical company reported a narrower-than-expected loss for Q1, with earnings per share (EPS) of -$0.05, beating analyst estimates. While the company still posted a net loss of $4.92 million, this represents a significant improvement compared to previous quarters. Avadel's net product revenue for the quarter reached $52.511 million, indicating strong sales performance.</p>\n\n<p>Investors were particularly encouraged by Avadel's optimistic outlook for 2025. The company raised its full-year guidance, now expecting to generate between $255 million and $265 million in net product revenue. This upward revision suggests growing confidence in the company's product pipeline and market position. The combination of better-than-expected quarterly results and an improved annual forecast appears to be driving the substantial pre-market rally in Avadel's stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AVDL","symbol_name":"Avadel Pharmaceuticals plc","start_time":0,"source_url":"","article_id":"1103586180","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103586180","pubTimestamp":1746616470,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Avadel Pharmaceuticals plc  shares surged 10.76% in pre-market trading on Wednesday following the company's release of its first-quarter 2025 financial results and an upward revision of its full-year guidance.The specialty pharmaceutical company reported a narrower-than-expected loss for Q1, with earnings per share  of -$0.05, beating analyst estimates. While the company still posted a net loss of $4.92 million, this represents a significant improvement compared to previous quarters. Avadel's ne","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AVDL":"Avadel Pharmaceuticals plc"},"translate_title":"股票赛道Avadel Pharmaceuticals因强劲的第一季度业绩和上调指引而盘前飙升10.76%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AVDL":1},"content_text":"Avadel Pharmaceuticals plc (AVDL) shares surged 10.76% in pre-market trading on Wednesday following the company's release of its first-quarter 2025 financial results and an upward revision of its full-year guidance.\nThe specialty pharmaceutical company reported a narrower-than-expected loss for Q1, with earnings per share (EPS) of -$0.05, beating analyst estimates. While the company still posted a net loss of $4.92 million, this represents a significant improvement compared to previous quarters. Avadel's net product revenue for the quarter reached $52.511 million, indicating strong sales performance.\nInvestors were particularly encouraged by Avadel's optimistic outlook for 2025. The company raised its full-year guidance, now expecting to generate between $255 million and $265 million in net product revenue. This upward revision suggests growing confidence in the company's product pipeline and market position. The combination of better-than-expected quarterly results and an improved annual forecast appears to be driving the substantial pre-market rally in Avadel's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}